CA2 - The Esmo Magnitude of Clinical Benefit Scale for Novel Cancer Medicines — Correspondence with Prioritization Decisions In Updating the Israeli National List of Health Services
| Autor: | Hammerman, A, Greenberg-Dotan, S, Feldhamer, I, Birnbaum, Y, Cherny, NI |
|---|---|
| Zdroj: | In Value in Health November 2015 18(7):A336-A336 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect